Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton sold 9,463 shares of Class A Common Stock in an open-market transaction at $30.00 per share. After the sale, Boughton directly holds 299,368 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
Hims & Hers Health Chief Financial Officer Oluyemi Okupe exercised stock options and sold shares of Class A Common Stock. On April 20, 2026, he exercised options for 7,000 shares at $11.53 and 5,553 shares at $5.01, acquiring a total of 12,553 shares. The same day, he completed an open-market sale of 19,645 shares at an average price of $29.9626, under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following these transactions, he held 262,954 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing notes the options exercised were fully vested, with some awards vesting monthly over four years beginning April 1, 2023.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported option exercises and share sales under a pre-arranged Rule 10b5-1 trading plan. On April 16–17, Okupe sold a total of 54,927 shares of Class A Common Stock in open-market transactions at average prices of $25.8964 and $27.8344. He also exercised stock options for 6,184 shares at an exercise price of $5.01 per share, converting derivative awards into common stock. Following these transactions, Okupe holds 270,046 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust, and retains stock options representing 129,403 shares expiring on February 23, 2032.
HIMS reported proposed sales of Class A common stock under Form 144. The filing lists proposed transfers tied to restricted stock vesting with amounts of 4,651 shares (12/15/2025) and 4,812 shares (03/15/2026). The excerpt also shows prior sales in the past three months: 4,651 shares sold on 02/27/2026 for $70,741.71 and 4,812 shares sold on 03/17/2026 for $118,808.28.
Hims & Hers Health, Inc. Chief Executive Officer Andrew Dudum reported a bona fide gift of a total of 845,866 shares of Class A Common Stock on April 9, 2026. The Form 4 shows two gift transactions of 422,933 shares each, recorded as non-derivative dispositions with no price paid.
After the gifts, Dudum holds 887,684 shares directly. He also has indirect holdings through several trusts, including 470,457 shares held by the Trustee of the Dudum Family Community Property Trust and additional blocks held in various Dudum family and GRAT trusts. These entries reflect estate and trust planning rather than open-market trading activity.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe exercised stock options and sold the resulting shares. He exercised options for 3,975 shares of Class A Common Stock at an exercise price of $5.01 per share, then sold 3,975 shares at an average price of $19.977 per share.
The option exercise and sale were made under a Rule 10b5-1 trading plan adopted on May 21, 2025. After these transactions, he holds 318,789 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
HIMS reported Form 144 sales by Oluyemi Okupe, who sold multiple blocks of Common Stock on various dates. The filing lists specific sale transactions including 4,490 shares on 02/03/2026 and 3,658 shares on 04/06/2026 with dollar proceeds recorded for each trade.
The Vanguard Group filed Amendment No. 5 to its Schedule 13G/A reporting on Hims & Hers Health Inc. common stock. The amendment states amount beneficially owned: 0 and percent of class: 0%, reflecting an internal realignment described as being made “in accordance with SEC Release No. 34-39538 (January 12, 1998).”
The filing explains certain subsidiaries or business divisions will report beneficial ownership separately after the realignment. The filing is signed by Ashley Grim, Head of Global Fund Administration.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe exercised stock options and sold shares in a pre-planned transaction. On March 20, 2026, he exercised options for 4,489 shares of Class A common stock at $5.01 per share and acquired the same number of shares.
That same day, he executed an open-market sale of 9,217 shares at an average price of $23.7677, with trades occurring between $23.73 and $23.92, under a Rule 10b5-1 trading plan adopted on May 21, 2025. After these transactions, he directly holds 318,789 shares and indirectly holds 7,853 shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. PAO Irene Becklund completed an open-market sale of 5,529 shares of Class A Common Stock at $24.69 per share. After this transaction, she directly holds 8,752 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating it was scheduled in advance rather than timed discretionarily.